Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06011629 · ClinicalTrials.gov registry record · Phase 4
Aquacel Hypersensitivity Dressing in TJAs
A Phase 4 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 396
- Enrollment target
NCT06011629: Completed Phase 4 study, sponsored by Rush University Medical Center.
NCT06011629 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 396 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06011629, a Phase 4 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 396 participants
- Enrollment target
Study Summary
The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
Primary Outcome
Using a classification of skin reactions from mild, moderate to severe
Interventions
- DEVICE Aquacel dressing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2025-06-03 |
| Phase | Phase 4 |
What the finished NCT06011629 record still lists
NCT06011629 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 1 intervention - of which Aquacel dressing is the first listed.
NCT06011629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06011629 about?
NCT06011629 is a clinical study titled "Aquacel Hypersensitivity Dressing in TJAs". The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compa...
What is the current status of trial NCT06011629?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 396 participants. The study started on 2023-08-18. Estimated completion is 2025-06-03.
What interventions are being tested in trial NCT06011629?
The interventions under investigation include: Aquacel dressing (DEVICE).
Who is sponsoring clinical trial NCT06011629?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06011629's enrollment target sits among peer trials
396 218th of 2000 higher than 1,783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI